Physician profile
Darlene I Mclaughlin
NPI 1306995097
$2,194.80
in general payments reported to CMS, 2019-2025
9 companies · $772 in 2025
The $772 reported for 2025 was more than what 89% of Psychiatric/Mental Health, Adult (Registered Nurse) providers received nationally (typical 2025 total: $121).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.95 · 2022: $440 · 2023: $500 · 2024: $443 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.80 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $967.79 | 2021-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $506.98 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $226.91 | 2024-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $184.83 | 2022-2023 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $114.30 | 2024 | Rexulti |
| Alkermes, INC. | $106.02 | 2023 | Lybalvi |
| Avanir Pharmaceuticals, INC. | $35.47 | 2021-2022 | |
| Lundbeck LLC | $32.09 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $20.41 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darlene Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.